Asset Details
Do you wish to reserve the book?
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
Do you wish to request the book?
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases
1994
Overview
Summary
Very few patients with liver metastases from colorectal cancer can be cured. We have investigated whether a treatment to slow the growth of liver metastases, hepatic-artery infusion of floxuridine, improves palliation in this setting. In a randomised study of 100 patients, we compared quality of life and survival in patients who received hepatic-artery infusion of floxuridine and in those who received conventional symptom palliation. 95% of control patient survival time was spent with normal quality-of-life scores, which suggests that the aim of treatment should be to prolong normal-quality survival rather than merely to sustain quality of life. There was a significant prolongation (p=0·03) in overall survival in floxuridine-treated patients compared with controls (median 405 vs 226 days). There were similar significant prolongations in normal-quality (ie, normal symptom scores) survival for physical symptoms (p=0·04), anxiety (p=0·04), and depression (p=0·04). This survival benefit was associated with significant reductions in metastasis size on computed tomography (p=0·001) and in serum carcinoembryonic antigen concentration (p=0·006) in floxuridine-treated patients. There was no evidence of treatment-related hepatotoxicity as assessed by serum aspartate aminotransferase and bilirubin measurements.
This is the first demonstration that survival can be prolonged with normal quality of life in patients with colorectal liver metastases. We conclude that hepatic-artery floxuridine infusion can be recommended for suitable patients.
Publisher
Elsevier Ltd,Lancet,Elsevier Limited
Subject
/ Aspartate Aminotransferases - blood
/ Biological and medical sciences
/ Carcinoembryonic Antigen - blood
/ Colorectal Neoplasms - pathology
/ Female
/ Floxuridine - therapeutic use
/ Gastroenterology. Liver. Pancreas. Abdomen
/ Humans
/ Infusions, Intra-Arterial - adverse effects
/ Infusions, Intra-Arterial - psychology
/ Liver
/ Liver Neoplasms - drug therapy
/ Liver Neoplasms - psychology
/ Male
/ Palliative Care - adverse effects
/ Palliative Care - psychology
/ Patients
/ Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
/ Survival
/ Tumors
